rightcasual.blogg.se

• #Srdx catheters plus#

#Srdx catheters plus#

In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 40% of the 250 plus Zacks industries. The FDA has granted 510(k) clearance for Surmodics' (NASDAQ:SRDX) Sublime Radial Access 0.014 Rapid Exchange Percutaneous Transluminal Angioplasty Dilation Catheter. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that the United States Food and Drug. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced enrollment of the first patient. The current consensus EPS estimate is -$0.47 on $26.87 million in revenues for the coming quarter and -$1.93 on $105.64 million in revenues for the current fiscal year. The Vetex Medical ReVene Thrombectomy Catheter has been engineered with a patented dynamic cage technology that enables the predictable removal of wall adherent thrombus in a single session without the need for thrombolytics. Business Wire - Thu Apr 20, 6:05AM CDT Surmodics, Inc. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead.

You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. So, the shares are expected to perform in line with the market in the near future. 018 RX PTA Dilatation Catheter Latest addition to the Sublime Radial Access Platform expands market opportunity by increasing size offering to treat larger vessels and providing the shaft length needed to treat more distal lesions. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. SRDX SurModics Inc Surmodics Announces Successful First Patient Uses of Sublime Radial Access. The company offers a wide range of advanced balloon catheter, thrombectomy, surface modification coatings and ultra-thin-walled catheter technologies to advance new medical devices, biomedical products, and enhance existing devices.

Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.Īhead of this earnings release, the estimate revisions trend for SurModics: mixed. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Įmpirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook.